title: Comorbidities at multiple sclerosis diagnosis.
abstract: The nature and frequency of comorbidities upon notification of multiple sclerosis (MS) are not well known. In France, MS is one of the 30 long-term illnesses (affections de longue durée, ALD) for which 100 % of patients' health care costs are covered by the main French health insurance system. We conducted a study among 22,087 patients who had contracted MS before their 45th birthday and had obtained ALD status between 1995 and 2004. Comorbidities diagnosed at MS notification were described. The age at which MS was registered in patients with a previous comorbidity was compared with that in those patients with no previous comorbidities. Among the 22,087 patients, 21,119 (95 %) had ALD status for MS only, 653 (3 %) had a comorbidity status diagnosed at the same time as MS. Of these comorbidities, 86.8 % could be grouped into five main categories: psychiatric disease (40.2 %), autoimmune disease (24.5 %), cardiovascular disease (16.2 %), cancer (12.2 %), and metabolic disease (9.0 %). Psychiatric disorders and diabetes were more frequent in MS patients than in the general population of the same age. The mean age at request for ALD status for MS in patients with no comorbidity was 33.6 ± 7.2 years, whereas it was 36.9 ± 6.5 years in those with comorbidities. Comorbidities at MS notification are rare. Psychiatric disorders and diabetes were more frequent in MS patients than in the general population.
authors.affiliation: Department of Neurology, University Hospital of Dijon, 3 rue du Faubourg Raines, 21000, Dijon, France.
authors.forename: Agnès
authors.initials: A
authors.lastname: Fromont
authors.forename: Christine
authors.initials: C
authors.lastname: Binquet
authors.forename: Fabien
authors.initials: F
authors.lastname: Rollot
authors.forename: Romain
authors.initials: R
authors.lastname: Despalins
authors.forename: Alain
authors.initials: A
authors.lastname: Weill
authors.forename: Laurence
authors.initials: L
authors.lastname: Clerc
authors.forename: Claire
authors.initials: C
authors.lastname: Bonithon-Kopp
authors.forename: Thibault
authors.initials: T
authors.lastname: Moreau
mesh_terms: D000293:Adolescent; D000328:Adult; D002908:Chronic Disease / Q000145:classification / Q000453:epidemiology*; D015897:Comorbidity; D005260:Female; D005602:France / Q000453:epidemiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000175:diagnosis* / Q000453:epidemiology*; D012189:Retrospective Studies; D012737:Sex Factors; D018709:Statistics, Nonparametric; D055815:Young Adult
references.citation: J Neurol Neurosurg Psychiatry. 2010 Dec;81(12):1413-4
references.pmid: 20724517
references.citation: Breast Cancer Res Treat. 2005 Feb;89(3):265-70
references.pmid: 15754125
references.citation: Mult Scler. 2010 Jul;16(7):855-61
references.pmid: 20463037
references.citation: PLoS Genet. 2009 Jan;5(1):e1000322
references.pmid: 19119414
references.citation: Curr Opin Immunol. 2009 Dec;21(6):596-605
references.pmid: 19896815
references.citation: Lancet Neurol. 2007 Jul;6(7):604-10
references.pmid: 17560172
references.citation: J Neurol Neurosurg Psychiatry. 2003 Jul;74(7):872-7
references.pmid: 12810770
references.citation: PLoS Genet. 2011 Aug;7(8):e1002254
references.pmid: 21852963
references.citation: Neurology. 2009 Jan 13;72(2):117-24
references.pmid: 18971448
references.citation: Ann Epidemiol. 1996 Sep;6(5):376-80
references.pmid: 8915467
references.citation: Lancet. 2002 Apr 27;359(9316):1461-5
references.pmid: 11988243
references.citation: JAMA. 1996 Nov 13;276(18):1473-9
references.pmid: 8903258
references.citation: Mult Scler. 2010 Jun;16(6):742-8
references.pmid: 20350959
references.citation: J Neurol Neurosurg Psychiatry. 2011 Mar;82(3):323-5
references.pmid: 21097550
references.citation: J Clin Epidemiol. 2001 Jul;54(7):661-74
references.pmid: 11438406
references.citation: Diabetes Care. 2003 Nov;26(11):3192-3
references.pmid: 14578268
references.citation: Mult Scler. 2009 Mar;15(3):385-92
references.pmid: 19153176
references.citation: Neurology. 2009 Mar 31;72(13):1170-7
references.pmid: 19332695
references.citation: Arch Neurol. 1971 Aug;25(2):105-11
references.pmid: 5571012
references.citation: Mult Scler. 2008 Sep;14(8):1091-8
references.pmid: 18728060
references.citation: J Clin Epidemiol. 1998 May;51(5):367-75
references.pmid: 9619963
references.citation: Acta Neurol Scand. 1991 Sep;84(3):214-20
references.pmid: 1950464
references.citation: J Manag Care Pharm. 2008 Apr;14(3 Suppl):2-6
references.pmid: 18439060
references.citation: Mult Scler. 2012 Sep;18(9):1310-9
references.pmid: 22328682
references.citation: Rev Prat. 2007 Jan 15;57(1):71-8
references.pmid: 17432005
references.citation: PLoS One. 2009;4(1):e4137
references.pmid: 19125193
references.citation: Mult Scler. 2012 Oct;18(10):1430-6
references.pmid: 22419672
references.citation: J Chronic Dis. 1970 Dec;23(7):455-68
references.pmid: 26309916
references.citation: Med Care. 1996 Nov;34(11):1093-101
references.pmid: 8911426
references.citation: Arch Neurol. 2006 Jul;63(7):1001-4
references.pmid: 16831970
references.citation: J Autoimmun. 2010 May;34(3):J168-77
references.pmid: 20034761